News
Carbon

CRISPR Unlocks Sweeter Tomatoes Without Yield Loss

Chinese scientists have achieved a significant advance in tomato agriculture by leveraging CRISPR–Cas9 to enhance sweetness without yield loss. The study targeted genetic regulators to overcome the trade-off between fruit size and sugar content, an enduring challenge in crop breeding.

By: Gorm Palmgren - Nov. 19, 2024
News

The study identified two key genes, SlCDPK27 and SlCDPK26, through a genome-wide association study (GWAS) that linked genetic variants to soluble solids content (SSC). The researchers pinpointed SlCDPK27 as a negative regulator of sugar accumulation based on its expression pattern, which negatively correlated with sugar levels.

SlCDPK27 was found to promote the degradation of a sucrose synthase by phosphorylating it, thereby functioning as a sugar brake. Further investigation identified SlCDPK26 as a paralogue with similar regulatory functions.

CRISPR-Cas9 was employed to inactivate these genes in cultivated tomato varieties. Mutants were created by targeting SlCDPK27 and SlCDPK26 with specific guide RNAs, introducing deletions that disrupted kinase activity necessary for sucrose synthase degradation. Functional assays confirmed the loss of kinase function in the edited genes, leading to up to 30% higher glucose and fructose levels in the fruits.

Notably, these edits did not affect fruit size or yield. Sensory panels validated the enhanced sweetness of the edited tomatoes. The modifications had minimal side effects, with a slight reduction in seed weight but normal germination.

The research was led by Sanwen Huang at the Chinese Academy of Agricultural Sciences, and it was published last week in Nature.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagNewsHashtagCARBON

News: CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Chronic Hepatitis B, HBV, (NCT06680232)
Sponsors:
Precision BioSciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine